PriceTargets.com logo

Ironwood Pharmaceuticals - IRWD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.67
  • Forecasted Upside: 27.65%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$11.49 As of 01/27/2023 01:00 AM ET
▲ +0.18 (1.59%)

This chart shows the closing price for IRWD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ironwood Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IRWD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IRWD

Analyst Price Target is $14.67
▲ +27.65% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Ironwood Pharmaceuticals in the last 3 months. The average price target is $14.67, with a high forecast of $16.00 and a low forecast of $13.00. The average price target represents a 27.65% upside from the last price of $11.49.

This chart shows the closing price for IRWD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Ironwood Pharmaceuticals. This rating has held steady since August 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/29/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/2/2022Capital One FinancialInitiated CoverageOverweight$15.00Low
8/16/2022Wells Fargo & CompanyBoost TargetEqual Weight$12.00 ➝ $13.00Low
4/22/2022Piper SandlerInitiated CoverageOverweight$16.00High
10/12/2021Morgan StanleyBoost TargetEqual Weight$13.00 ➝ $14.00Low
7/16/2021Morgan StanleyBoost TargetEqual Weight$11.00 ➝ $12.00Low
7/6/2021Northland SecuritiesReiterated RatingBuy$15.00Medium
2/25/2021Morgan StanleyLower TargetEqual Weight$12.00 ➝ $11.00High
11/6/2020Credit Suisse GroupBoost TargetNeutral$11.00 ➝ $12.00High
11/6/2020Morgan StanleyBoost TargetEqual Weight$11.00 ➝ $12.00Medium
9/30/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$14.00 ➝ $9.00High
8/7/2020Morgan StanleyBoost TargetEqual Weight$10.00 ➝ $11.00Low
8/3/2020Northland SecuritiesReiterated RatingBuyHigh
7/15/2020Morgan StanleyLower TargetEqual Weight$11.00 ➝ $10.00Low
6/17/2020Northland SecuritiesInitiated CoverageOutperform$14.00High
6/1/2020Credit Suisse GroupLower TargetNeutral$12.00 ➝ $11.00Low
5/11/2020HC WainwrightLower TargetNeutral$13.00 ➝ $11.00High
5/7/2020Credit Suisse GroupReiterated RatingHold$12.00Low
5/7/2020Morgan StanleyLower TargetEqual Weight$12.00 ➝ $11.00Low
4/30/2020Wells Fargo & CompanyLower TargetOverweight$16.00 ➝ $15.00Medium
4/15/2020Morgan StanleyLower TargetEqual Weight$13.00 ➝ $12.00High
1/28/2020HC WainwrightReiterated RatingHold$13.00Low
1/21/2020HC WainwrightReiterated RatingHold$13.00Low
9/13/2019CowenSet TargetHold$12.00Low
7/31/2019WedbushBoost TargetNeutral$11.00 ➝ $12.00High
7/10/2019Credit Suisse GroupReiterated RatingNeutralLow
6/24/2019HC WainwrightSet TargetHold$13.00Low
5/6/2019WedbushReiterated RatingNeutral$14.00 ➝ $11.00Low
5/3/2019Morgan StanleySet TargetHold$13.00Low
5/2/2019MizuhoSet TargetBuy$20.00High
3/27/2019Morgan StanleyUpgradeUnderweight ➝ Equal$11.00 ➝ $14.00High
3/22/2019Credit Suisse GroupSet TargetHold$16.00Low
2/26/2019Wood & CompanyInitiated CoverageBuyMedium
2/25/2019GMP SecuritiesUpgradeSell ➝ Neutral$11.50 ➝ $14.00High
2/25/2019HC WainwrightUpgradeSell ➝ Neutral$11.50 ➝ $14.00Low
2/14/2019BTIG ResearchSet TargetBuy$19.00High
1/31/2019Wood & CompanyReiterated RatingBuyMedium
1/24/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$11.00 ➝ $13.00Low
1/15/2019MizuhoBoost TargetBuy$20.00High
12/10/2018HC WainwrightSet TargetSell$12.00Low
11/19/2018MizuhoLower TargetBuy$15.00Low
11/7/2018WedbushReiterated RatingNeutralMedium
11/7/2018Morgan StanleySet TargetSell$11.00Medium
11/7/2018JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Underweight$20.00 ➝ $11.00High
11/7/2018Credit Suisse GroupReiterated RatingOutperform ➝ Neutral$22.00 ➝ $19.00High
11/7/2018BTIG ResearchSet TargetBuy$17.00High
11/1/2018Wells Fargo & CompanyLower TargetOutperform$18.50Low
10/31/2018Wells Fargo & CompanySet TargetBuy$19.00High
10/31/2018HC WainwrightSet TargetSell$13.00Medium
9/17/2018HC WainwrightSet TargetSell$13.00High
8/22/2018HC WainwrightSet TargetSell$13.00Low
8/8/2018Wells Fargo & CompanySet TargetOutperform ➝ Buy$22.00 ➝ $23.00Low
8/7/2018HC WainwrightSet TargetSell$13.00Medium
7/23/2018HC WainwrightInitiated CoverageSell$12.50Low
7/18/2018CowenReiterated RatingOutperform ➝ Market PerformHigh
5/31/2018Wells Fargo & CompanyBoost TargetOutperform ➝ Outperform$18.00 ➝ $20.00Medium
5/30/2018Wells Fargo & CompanySet TargetBuy$22.00High
5/9/2018Morgan StanleyDowngradeEqual ➝ Equal WeightMedium
5/9/2018Morgan StanleyReiterated RatingEqual Weight ➝ Underweight$13.00Low
5/2/2018BarclaysBoost TargetEqual Weight ➝ Equal Weight$16.00 ➝ $20.00Low
5/2/2018MizuhoUpgradeNeutral ➝ Buy$16.00 ➝ $24.00Medium
4/19/2018Berenberg BankInitiated CoverageBuy$25.00Medium
4/9/2018Wells Fargo & CompanySet TargetBuy$18.00High
(Data available from 1/29/2018 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
9/1/2022
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 6 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023

Current Sentiment

  • 6 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Ironwood Pharmaceuticals logo
Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.
Read More

Today's Range

Now: $11.49
Low: $11.31
High: $11.51

50 Day Range

MA: $11.88
Low: $11.18
High: $12.56

52 Week Range

Now: $11.49
Low: $9.73
High: $12.95

Volume

1,097,376 shs

Average Volume

1,849,335 shs

Market Capitalization

$1.76 billion

P/E Ratio

12.09

Dividend Yield

N/A

Beta

0.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Ironwood Pharmaceuticals?

The following equities research analysts have issued reports on Ironwood Pharmaceuticals in the last twelve months: Capital One Financial Co., Piper Sandler, StockNews.com, and Wells Fargo & Company.
View the latest analyst ratings for IRWD.

What is the current price target for Ironwood Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Ironwood Pharmaceuticals in the last year. Their average twelve-month price target is $14.67, suggesting a possible upside of 27.6%. Piper Sandler has the highest price target set, predicting IRWD will reach $16.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $13.00 for Ironwood Pharmaceuticals in the next year.
View the latest price targets for IRWD.

What is the current consensus analyst rating for Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IRWD will outperform the market and that investors should add to their positions of Ironwood Pharmaceuticals.
View the latest ratings for IRWD.

What other companies compete with Ironwood Pharmaceuticals?

Other companies that are similar to Ironwood Pharmaceuticals include Dynavax Technologies, MannKind, Geron, Ligand Pharmaceuticals and ImmunoGen. Learn More about companies similar to Ironwood Pharmaceuticals.

How do I contact Ironwood Pharmaceuticals' investor relations team?

Ironwood Pharmaceuticals' physical mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The biotechnology company's listed phone number is (617) 621-7722 and its investor relations email address is [email protected] The official website for Ironwood Pharmaceuticals is www.ironwoodpharma.com. Learn More about contacing Ironwood Pharmaceuticals investor relations.